Novo Nordisk A-S
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $71,311,000 | $68,060,000 | $65,349,000 | $65,863,000 |
Gross Profit | 60,003,000 | 57,786,000 | 55,433,000 | 55,849,000 |
EBITDA | 37,355,000 | 34,779,000 | 35,328,000 | 28,511,000 |
EBIT | 35,205,000 | 31,634,000 | 32,414,000 | 25,519,000 |
Net Income | 27,301,000 | 20,050,000 | 25,407,000 | 21,963,000 |
Net Change In Cash | 71,311,000 | 68,060,000 | 65,349,000 | 65,863,000 |
Free Cash Flow | 31,346,000 | 37,265,000 | 5,305,000 | -6,885,000 |
Cash | 57,018,000 | 52,821,000 | 6,324,000 | 14,392,000 |
Basic Shares | 4,453,746 | 4,465,400 | 4,470,500 | 4,477,400 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $232,261,000 | $176,954,000 | $140,800,000 | $126,946,000 |
Gross Profit | 196,496,000 | 148,506,000 | 117,142,000 | 106,014,000 |
EBITDA | 114,629,000 | 82,040,000 | 65,394,000 | 59,273,000 |
EBIT | 105,216,000 | 75,438,000 | 60,083,000 | 53,997,000 |
Net Income | 83,683,000 | 55,525,000 | 47,757,000 | 42,138,000 |
Net Change In Cash | 232,261,000 | 176,954,000 | 140,800,000 | 126,946,000 |
Free Cash Flow | 70,012,000 | 64,134,000 | 47,615,000 | 29,870,000 |
Cash | 14,392,000 | 12,653,000 | 10,720,000 | 12,757,000 |
Basic Shares | 4,494,800 | 4,544,600 | 4,606,200 | 4,680,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.90 |
2024-06-30 | $0.66 |
2024-03-31 | $0.83 |
2023-12-31 | $0.71 |
